ClinicalTrials.gg
RecruitingNCT07136519Updated Oct 29, 2026

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

A Phase 2 interventional study of Toripalimab and Omega-3 in Nasopharyngeal Carcinoma (NPC), sponsored by Affiliated Hospital of Guangdong Medical University. Recruiting at 3 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Affiliated Hospital of Guangdong Medical University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 29, 2026Now RecruitingStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies testing toripalimab in Nasopharyngeal Carcinoma — 22 open to participants now, 26 under way, 7 of them phase 3. toripalimab · Nasopharyngeal Carcinoma.

Planned enrollment
32nd of 36
30 · median 67
Started
2025
with 7 others
Phase 2
24 of 36
13 open now
Primary completion
2029-12
later than 24 of 25 live
Registered
31st of 36
by date
Lead sponsor
2 of 36
Affiliated Hospital of Guangdong Medical University

Among the 36 studies testing toripalimab in Nasopharyngeal Carcinoma, this one is the 32nd largest by planned enrollment, is one of 8 that started in 2025, is one of 24 in phase 2, reaches primary completion later than 24 of the 25 other live ones, and was the 31st registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

22 of the 36 studies testing toripalimab in Nasopharyngeal Carcinoma are open now, in 2 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

About toripalimab

toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing toripalimab in Nasopharyngeal Carcinoma, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the efficacy, adverse reactions, nutritional status analysis, and quality of life analysis of Toripalimab Plus Induction Chemotherapy Followed by Radiation Therapy Combined with Omega-3 in the treatment of locally advanced nasopharyngeal carcinoma.

Read the detailed description

After being informed about the study and potential risks, all patients giving written informedconsent will undergo a 1-week screening period to determine eligibility for study entry. In week 0, eligible patients will be enrolled in a clinical study on the combination of Toripalimab, induction chemotherapy, sequential radiotherapy, and OMEGA-3 for the treatment of locally advanced nasopharyngeal carcinoma. Induction chemotherapy stage: Toripalimab 240mg d1, paclitaxel (albumin bound) 260mg/m2 d1, cisplatin 80mg/m2 d2 Q3W X 3 cycles. Radiotherapy stage: IMRT+Toripalimab 240mg Q3W X 3 cycles+Omega-3 (6 pills qd during radiotherapy). IMRT:GTVnx 69.96Gy,GTVnd 69.96Gy,CTV1 60Gy,CTV2 54Gy。 Maintenance treatment: Toripalimab 240mg Q3W X 6 cycles.

03

Conditions studied

  • Nasopharyngeal Carcinoma (NPC)

Keywords

  • Toripalimab
  • Omega-3
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written can be provided, and understanding and compliance with research requirements and evaluation schedules are required.
  • On the date of signing the informed consent form, the age range is between 18 and 65 years old (or the legal age specified by local laws).
  • Pathological diagnosis is non keratinizing carcinoma of the nasopharynx (differentiated or undifferentiated, i.e. WHO classification II or III).
  • Clinical staging is anyTN2-3M0 or T4N1M0 (AJCC8th/UICC staging).
  • score is 0-1 points.
  • (HGB) ≥ 90g/L, white blood cell (WBC) ≥ 4.0 × 109/L, (PLT) ≥ 100 × 109/L.
  • Liver function: and AST\<2.5 times the (ULN), total \<2.0 × UL, serum albumin ≥ 28g/L.
  • Renal function: Serum creatinine\<1.5 × ULN or rate (CrCl) calculated value ≥ 60mL/min (Cockcroft Gault formula).
  • Thyroid stimulating hormone (TSH) ≤ 1 × ULN (if abnormal, FT3 and FT4 levels should be examined simultaneously. If FT3 and FT4 levels are normal, they can be included in the group).
  • The (INR) and activated partial thromboplastin time (APTT) are ≤ 1.5 × ULN (unless the subject is receiving anticoagulant treatment and the coagulation parameters (PT/INR and APTT) are within the expected range of anticoagulant treatment at the time of screening).

Exclusion criteria

Exclusion Criteria:

  • Nasopharyngeal cancer patients with recurrence and distant .
  • Pathology shows keratinized squamous cell carcinoma (WHO classification type I).
  • Patients who have undergone radiotherapy or systemic chemotherapy before.
  • Pregnant or lactating women who are in the reproductive period and have not taken effective measures.
  • positive.
  • Have suffered from other malignant tumors (except for cured basal cell carcinoma or cervical carcinoma in situ).
  • Patients who have been treated with (CTLA-4, PD-1, PD-L1, etc.).
  • Patients with immunodeficiency diseases and a history of organ transplantation.
  • Patients who have been treated with high-dose , anti-cancer monoclonal antibodies, or other agents within 4 weeks.
  • Patients with significantly impaired heart, liver, lung, kidney, and bone marrow function.
  • Simultaneously using other drugs or in other clinical trials.
  • Refusal or inability to sign the form for participation in the trial.
  • Individuals with personality or mental disorders, without civil capacity or with limited civil capacity.
  • B surface antigen (HBsAg) is positive and the peripheral blood hepatitis B virus deoxyribonucleic acid (HBV DNA) is ≥ 1000 cps/ml.
  • Patients with positive antibody test results are only eligible for this study if their HCV RNA polymerase chain reaction test results are negative.
  • Patients who have experienced any bleeding events with a severity rating of 3 or above in CTCAE5.0 within the first 4 weeks of screening and are deemed to have a high risk of bleeding by the researchers.
  • If there have been any arterial/venous thrombotic events within the 6 months prior to the start of screening, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism.
  • Patients with hypertension who cannot be reduced to the normal range through antihypertensive medication (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg); Based on the average of BP readings obtained from ≥ 2 measurements, there has been a history of hypertensive crisis or hypertensive encephalopathy.
  • Past or current inflammatory bowel disease (such as Crohn's disease, ulcerative colitis, or chronic diarrhea); History of previous or existing gastrointestinal perforation and/or fistula.
  • Known history of active pulmonary tuberculosis (TB). Subjects suspected of having active TB should undergo chest X-ray, sputum examination, and exclusion based on clinical symptoms and signs.
  • Other serious, uncontrolled internal medical conditions and infections, or other to treatment, or any condition that researchers believe may pose a risk to receiving the study drug treatment, or interfere with the evaluation of the study drug, subject safety, or analysis of the study results.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Toripalimab Plus Omega-3

    Toripalimab Plus Induction Chemotherapy Followed by Radiation Therapy Combined with Omega-3

    Drug: Toripalimab · Dietary Supplement: Omega-3 · Radiation: radiotherapy · Drug: Paclitaxel (albumin bound) · Drug: Cisplatin

Interventions

06

What researchers measure

Primary outcomes

  1. 2-year progression free survival period

    It refers to the probability of disease progression or death from any cause objectively recorded from a random date within two years, evaluated according to RECIST v1.1.

    Time frame: From enrollment to the end of treatment at 2 years

Secondary outcomes

  1. objective response rate

    It refers to the proportion of patients who achieve complete or partial remission, evaluated by an independent review committee based on RECIST v1.1 for all randomized patients with measurable disease at baseline.

    Time frame: From enrollment to the end of treatment at 2 years

  2. Overall survival

    It refers to the period from a random date to the date of death for any reason, evaluated according to RECIST v1.1.

    Time frame: From enrollment to the end of treatment at 2 years

  3. Adverse reactions

    According to the National Cancer Institute's Common Terminology Criteria for Adverse Events v5.0 grading.

    Time frame: From enrollment to the end of treatment at 2 years

  4. Quality of life score

    Evaluate through the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Head and Neck Cancer-35 module and Core 30.For EORTC QLQ - H\&N35: Title: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Head and Neck Cancer - 35 Range: Items 1-4, subscales vary. Meaning: Higher symptom scores = worse outcome; higher functional scores (if any) = better function. For EORTC QLQ - C30: Title: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Range: 0-100 for scales. Meaning: Higher functional scores = better outcome; higher symptom scores = worse outcome. Align with standardized scoring.

    Time frame: From enrollment to the end of treatment at 2 years

  5. Nutritional status analysis

    Assess nutritional status based on body mass index.Unabbreviated scale title: Body Mass Index (BMI) Minimum and maximum values: Theoretically, BMI can range from near 0 to over 100, but in practical clinical and research contexts for assessing human nutritional status, the typical relevant range is approximately 10 to 60. Higher scores meaning: A BMI within the normal range (18.5 - 24.9 for adults) indicates a better nutritional outcome (appropriate weight for height, supporting good health). Scores lower than 18.5 (underweight) mean a worse outcome (increased risk of nutritional deficiencies). Scores higher than 24.9 (overweight or obese, with obesity classes having higher values) also mean a worse outcome (increased risk of various health problems related to excess weight).

    Time frame: From enrollment to the end of treatment at 2 years

07

Study locations

2 of 3 sites recruiting
  • Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong 524001, China
    Recruiting
    • Haiqing Luo, M.D. · Contacthqluo@126.com · +86 13729196345
    • haiqing Luo, M.D. · Principal investigator
  • Guangdong Nongken Central Hospital
    Zhanjiang, Guangdong 524002, China
    Not yet recruiting
    • ruiwen Huang · Contact718064629@qq.com · +86 13356519222
    • ruiwen Huang · Sub investigator
  • The Second Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong 524003, China
    Recruiting
    • hong Liu · Contact274803913@qq.com · +86 13828293012
    • hong Liu · Sub investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data (IPD), including de - identified demographic information, clinical outcomes, and treatment details, will be shared with qualified researchers upon request. Access will be provided via a secure data repository after review and approval of a data access request form to ensure compliance with ethical and legal standards.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: IPD will become available 6 months after the primary study results are published in a peer - reviewed journal. The data will remain accessible for a period of 5 years to facilitate secondary analyses and research replication.

Access criteria: To access IPD, researchers must: (1) Be affiliated with a recognized academic or research institution; (2) Submit a request detailing the research question, methodology, and how the data will contribute to advancing knowledge in the field; (3) Provide evidence of ethical approval from their local IRB for the proposed secondary analysis; (4) Agree to use de - identified data only and not attempt to re - identify participants. Access is granted at the discretion of the study's data governance board after a full review of the request.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2029, 53 months after the start.

Of 128 non-industry phase 2 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 74. This study's planned 53 months is close to that.

Counting every sponsor, half of 143 studies reached it within 43 months; a quarter within 28 and three quarters within 65.

Start moved once since we started tracking on Sep 25, 2026: Aug 2025 → Jul 2025, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Aug 22, 2025
StartActual
Jul 30, 2025was Aug 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 29, 2026
Sites
3 sites added — first site in China
Show 3 added (3 China)
  • Affiliated Hospital of Guangdong Medical University · Zhanjiang, China
  • Guangdong Nongken Central Hospital · Zhanjiang, China
  • The Second Affiliated Hospital of Guangdong Medical University · Zhanjiang, China
Oct 29, 2026
Start date
Aug 22, 2025→Jul 30, 2025 (actual)
Oct 29, 2026
Documents
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Not yet recruiting→Recruiting
    Documents Study protocol ↗ posted · Informed consent form ↗ updated
    3 sites added — first site in China
    Show 3 added (3 China)
    • Affiliated Hospital of Guangdong Medical University · Zhanjiang, China
    • Guangdong Nongken Central Hospital · Zhanjiang, China
    • The Second Affiliated Hospital of Guangdong Medical University · Zhanjiang, China
    Start date Aug 22, 2025→Jul 30, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07136519
Lead sponsor
Affiliated Hospital of Guangdong Medical University
Responsible party
Haiqing Luo (Director of Head and Neck Oncology Department, Affiliated Hospital of Guangdong Medical University) — Principal investigator
First posted
Aug 22, 2025
Start date
Jul 30, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 29, 2026

Study contacts

Haiqing Luo, doctor
Contact
hqluo@126.com
8613729196345
Haiqing Luo, doctor
principal investigator · Guangdong Medical University Affiliated Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Toripalimab · Omega-3 fatty acid

Start the discussion